CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study of Brentuximab Vedotin (SGN35) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01780662
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:26.209195+00:00
Published At: 2019-10-01T00:00:00+00:00
Record Updated At: 2021-10-28
Results Posted At: 2019-10-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Adult Hodgkin Lymphoma", "Recurrent Childhood Hodgkin Lymphoma", "Refractory Childhood Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-10-28"
protocolSection.identificationModule.nctId: "NCT01780662"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Study of Brentuximab Vedotin (SGN35) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-10-01"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.